Loss of response to melatonin treatment is associated with slow melatonin metabolism.

BACKGROUND In some of our patients with intellectual disability (ID) and sleep problems, the initial good response to melatonin disappeared within a few weeks after starting treatment, while the good response returned only after considerable dose reduction. The cause for this loss of response to melatonin is yet unknown. We hypothesise that this loss of response is associated with slow melatonin metabolism. METHOD In this study, we determined melatonin clearance in two female (aged 61 and 6 years) and one male (aged 3 years) patients who had chronic insomnia, late melatonin onset and mild ID, and whose sleep quality worsened a few weeks after initial good response to melatonin treatment, suggesting melatonin tolerance. After a 3-week washout period, patients received melatonin 1.0, 0.5 or 0.1 mg, respectively. Salivary melatonin level was measured just before melatonin administration, and 2 and 4 h thereafter. After this melatonin clearance test, melatonin treatment was resumed with a considerably lower dose. RESULTS In all patients melatonin concentrations remained >50 pg/mL at 2 and 4 h after melatonin administration. After resuming melatonin treatment sleep problems disappeared. The same procedure was followed in three patients who did not show loss of response to melatonin after 6 months of treatment. In all patients in the control group melatonin concentrations decreased between 2 and 4 h after melatonin administration with a mean of 83%. CONCLUSION We hypothesise that loss of response to melatonin treatment can be caused by slow metabolisation of exogenous melatonin. As melatonin is metabolised in the liver almost exclusively by cytochrome P450 enzyme CYP1A2, this slow melatonin metabolism is probably due to decreased activity/inducibility of CYP1A2. In patients with loss of response to melatonin, a melatonin clearance test should be considered and a considerably dose reduction is advised.

[1]  Seithikurippu R. Pandi-Perumal,et al.  Dim light melatonin onset (DLMO): A tool for the analysis of circadian phase in human sleep and chronobiological disorders , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  A. Lewy,et al.  Melatonin shifts human circadian rhythms according to a phase-response curve. , 1992, Chronobiology international.

[3]  A. D. Rodrigues,et al.  Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  R. Didden,et al.  Melatonin for Chronic Insomnia in Angelman Syndrome: A Randomized Placebo-Controlled Trial , 2008, Journal of child neurology.

[5]  J. Emens,et al.  Melatonin Entrains Free‐running Blind People According to a Physiological Dose‐response Curve , 2005, Chronobiology international.

[6]  J. Lafitte,et al.  Five novel natural allelic variants—951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)—of the human CYP1A2 gene in a French Caucasian population , 2001, Human mutation.

[7]  G. Miller,et al.  Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. , 2001, Biochemistry.

[8]  Ncbi National Center for Biotechnology Information , 2008 .

[9]  A. Coenen,et al.  Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[10]  B. Malow,et al.  Melatonin for Insomnia in Children With Autism Spectrum Disorders , 2008, Journal of child neurology.

[11]  R. Didden,et al.  Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta‐analysis , 2009, Developmental medicine and child neurology.

[12]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[13]  M. Laudon,et al.  Clinical trials of controlled‐release melatonin in children with sleep–wake cycle disorders , 2000, Journal of pineal research.

[14]  M. Sugama,et al.  [Usefulness of melatonin for developmental sleep and emotional/behavior disorders--studies of melatonin trial on 50 patients with developmental disorders]. , 1999, No to hattatsu = Brain and development.

[15]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[16]  J. Emens,et al.  Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period , 2002, Chronobiology international.

[17]  T. Kamataki,et al.  Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  K. B. Heijden,et al.  Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia , 2005, Journal of sleep research.

[19]  G. Kerkhof,et al.  Correlation between concentrations of melatonin in saliva and serum in patients with delayed sleep phase syndrome. , 1998, Therapeutic drug monitoring.

[20]  Tuomas Korhonen,et al.  Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin. , 2006, Basic & clinical pharmacology & toxicology.

[21]  R. Hayes,et al.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. , 1992, Pharmacogenetics.

[22]  Bruno Claustrat,et al.  The basic physiology and pathophysiology of melatonin. , 2005, Sleep medicine reviews.

[23]  R. Wurtman,et al.  Melatonin: a sleep-promoting hormone. , 1997, Sleep.

[24]  J. Fourtillan,et al.  Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. , 2000, Biopharmaceutics & drug disposition.

[25]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[26]  L. Bertilsson,et al.  Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study , 2001, Clinical pharmacology and therapeutics.

[27]  R. Wurtman,et al.  Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. V. van Someren,et al.  Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[29]  Shu-Feng Zhou,et al.  Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2 , 2009, The AAPS Journal.

[30]  A. J. McArthur,et al.  Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment , 1998, Developmental medicine and child neurology.

[31]  I. Zhdanova,et al.  Melatonin as a hypnotic: pro. , 2005, Sleep medicine reviews.